Refractory asthma, also commonly referred to as severe refractory asthma or severe treatment-resistant asthma, is a subset of severe asthma.
It refers to asthma that remains poorly controlled despite optimized, high-dose inhaled treatments and addressing modifiable factors.
Refractory asthma is now more accurately termed severe asthma, defined as asthma that remains uncontrolled despite adherence to maximal optimized high-dose inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA) treatment and management of contributory factors, or that worsens when high-dose treatment is decreased.
Uncontrolled asthma includes poor symptom control (frequent symptoms, reliever use, activity limitation, night waking) and/or frequent exacerbations (≥2 per year requiring oral corticosteroids or ≥1 per year requiring hospitalization).
Uncontrolled asthma — Persistent symptoms (e.g., frequent reliever use, night waking, activity limitation) and/or frequent exacerbations (≥2/year requiring oral corticosteroids or ≥1 hospitalization).
Difficult-to-treat asthma — Uncontrolled despite medium- or high-dose inhaled corticosteroids (ICS) plus a second controller (usually a long-acting beta-agonist, LABA), or requiring high-dose therapy (or maintenance oral corticosteroids) to stay controlled.
This often stems from modifiable issues.
Severe asthma (including refractory) — A subset of difficult-to-treat asthma where symptoms remain uncontrolled despite confirmed adherence to maximal optimized high-dose ICS-LABA, proper inhaler technique, management of comorbidities (e.g., GERD, sinusitis, obesity), and avoidance of triggers.
It may worsen if high-dose therapy is reduced. “Refractory” highlights resistance to standard high-dose inhaled therapy, though biologics have made many cases more treatable.
Severe asthma affects about 3–5% (up to ~10% in some estimates) of people with asthma but accounts for a disproportionate share of hospitalizations, costs, and mortality risk.
True refractory/severe asthma often involves persistent airway inflammation: usually Type 2-high, with elevated eosinophils, FeNO (exhaled nitric acid) or allergic drivers, but many refractory cases are initially due to:
Incorrect inhaler technique or poor adherence.
Undiagnosed/untreated comorbidities (e.g., chronic rhinosinusitis, GERD, obesity, vocal cord dysfunction).
Environmental triggers (smoking, allergens, occupational exposures).
Misdiagnosis (symptoms from COPD, heart failure, or inducible laryngeal obstruction.
True biological resistance (e.g., persistent Type 2 inflammation despite high-dose inhaled corticosteroids (ICS).
Treatment:
Core treatment starts with high-dose ICS-LABA (long acting beta agonists) often as maintenance and reliever therapy (MART) with ICS-formoterol).
Add-on treatment include:
Long-acting muscarinic antagonists (e.g., tiotropium).
Low-dose azithromycin for non-Type 2 inflammation in some cases.
Biologic therapies — Key advance for true severe/refractory asthma, especially Type 2-high phenotypes.
These targeted monoclonal antibodies reduce exacerbations, often by 50–70%, and improve lung function, and decrease oral corticosteroid needs.
Approved biologics for severe asthma include:
Six biologic agents are FDA-approved for severe asthma, each targeting specific inflammatory pathways and showing 30-70% reduction in severe exacerbations compared to placebo.
Omalizumab (Xolair) — Targets IgE (allergic asthma). Omalizumab (anti-IgE): For severe allergic asthma in patients ≥6 years with sensitization to perennial aeroallergens. Mepolizumab, benralizumab, reslizumab (anti-IL-5/IL-5Rα): For severe eosinophilic asthma with blood eosinophils ≥150/μL (≥400/μL for reslizumab). Mepolizumab (Nucala), Reslizumab (Cinqair), Benralizumab (Fasenra) — Target IL-5/eosinophils (eosinophilic asthma). Dupilumab (Dupixent) — Targets IL-4/IL-13 (broader Type 2 inflammation). Dupilumab (anti-IL-4Rα): For severe eosinophilic/Type 2 asthma or oral corticosteroid-dependent asthma in patients ≥6 years. Tezepelumab (Tezspire) — Targets TSLP-works across phenotypes, including non-Type 2; often first-line for broader applicability. Tezepelumab (anti-TSLP): For severe asthma in patients ≥12 years, effective across broad biomarker ranges.
Other options in select cases include low-dose maintenance oral corticosteroids or procedures like bronchial thermoplasty for certain adults with persistent symptoms.
Severe asthma diagnosis has to rule out modifiable factors. including incorrect inhaler technique (up to 80% of patients), poor adherence, smoking, comorbidities..
Phenotyping is essential for biologic selection.
Key biomarkers include blood eosinophils ≥150/μL, fractional exhaled nitric oxide (FeNO) ≥20 ppb, sputum eosinophils ≥2%, and perennial aeroallergen sensitization.
Higher baseline eosinophil counts predict better responses to biologic therapy.
Other add-on options include long-acting muscarinic antagonists (LAMAs), which provide modest exacerbation reduction, and low-dose azithromycin in adults.
Maintenance oral corticosteroids should be used only as a last resort due to serious cumulative side effects.
A trial of at least 4 months is needed to assess biologic response, with ongoing monitoring of symptom control, exacerbations, lung function, and treatment of Type 2 comorbidities like nasal polyps.